A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

This study tests whether adding bicalutamide — a hormone-blocking medication — to standard BCG bladder therapy can improve outcomes for men with non-muscle-invasive bladder cancer. **You may be eligible if...** - You are a male aged 18 or older - You have been diagnosed with non-muscle-invasive bladder cancer confirmed by biopsy - Your urologist has recommended a course of BCG (immunotherapy placed into the bladder) **You may NOT be eligible if...** - You have received BCG treatment within the last 5 years - You had a heart attack or were hospitalized for heart failure in the past 12 months - You have uncontrolled high blood pressure - You have liver disease with significantly elevated liver enzymes - You are on androgen replacement therapy or being treated for prostate cancer with hormonal therapy - You are taking the blood thinner warfarin (Coumadin) Talk to your doctor to see if this trial is right for you.